Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555850 | 1.00 | ACE2 (0.50) | ACE2ALDH1A1ALOX15TDP1GAA | |
| SCHEMBL6858554 | 0.86 | TSHR (0.44) | ACE2ALDH1A1ALOX15GAAKMT2A | |
| SCHEMBL1904536 | 0.85 | TSHR (0.57) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| SCHEMBL21961149 | 0.85 | TSHR (0.57) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| SCHEMBL9040914 | 0.85 | ALDH1A1 (0.43) | ACE2ALDH1A1KMT2AMAPTTSHR | |
| SCHEMBL8878990 | 0.84 | ALDH1A1 (0.50) | ACE2ALDH1A1ALOX15TDP1GAA | |
| SCHEMBL11187515 | 0.84 | AKR1C3 (0.48) | ACE2ALDH1A1GAAKMT2AMAPT | |
| SCHEMBL3380036 | 0.83 | IRAK4 (0.47) | ACE2ALDH1A1GAAKMT2AMAPT | |
| SCHEMBL8881631 | 0.82 | ACE2 (0.46) | ACE2ALDH1A1ALOX15TDP1GAA | |
| Acetic Acid SCHEMBL8193458 | 0.82 | BCAT2 (0.44) | ACE2ALDH1A1KMT2AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106957217-B | Polyhydric phenol compound for resist composition | 三菱瓦斯化学株式会社 | 2020-07-24 | — | — | CN | disclosed |
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6693199-B2 | DEPROTECTING CARBAMATE GROUP AND AMIDATING IN PRESENCE OF SUCH AS HYDROXYBENZOTRIAZOLE HYDRATE PROMOTER | AGOURON PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1340744-A2 | Hiv protease inhibitors | Agouron Pharmaceuticals, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6525215-B2 | As antiviral agents suitable for therapy of patients or hosts infected with the HIV virus, which is known to cause AIDS | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020077338-A1 | HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2002-06-20 | — | — | US | disclosed |
| US-6271235-B1 | VIRICIDE | AGOURON PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6162812-A | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5827891-A | FOR TREATMENT OF AIDS, BLOCKING REPLICATION OF HIV VIRUS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| US-5639922-A | CONTACTING AROMATIC PRIMARY AND TERTIARY HYDROPEROXIDES MIXTURE OBTAINED BY OXIDATION OF ALKYLAROMATIC COMPOUNDS WITH AN ALKALI OR ALKALINE ORGANIC AROMATIC CARBOXYLIC ACID SALT, DECOMPOSING WITH ACID CATALYST FORMING ALKYL PHENOLS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0741719-A4 | INTERMEDIATE AND PROCESS FOR MAKING | LILLY CO ELI (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0741719-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077338-A1 | HIV protease inhibitors | PREP, PRSS1, SERPINB1 | ACE2 63/4885ALDH1A1 3232/4885ALOX15 1261/4885 |
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | ACE2 93/4885ALDH1A1 1046/4885ALOX15 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.